Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Vanguard Value Index Fund ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Vanguard Value Index Fund ETF trades at $221.23 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 91.7× Dyne Therapeutics Inc. Common Stock's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Vanguard Value Index Fund ETF for 143 Days on average.
| DYN | VTV | |
|---|---|---|
Market Cap | $2.86B | $262.40B |
Volume | 3,341,579 | 1,774,364 |
Sector | Health | — |
52-Week High | $26.78 | $227.51 |
52-Week Low | $14.60 | $182.89 |
Typical Hold Time | 0 Days | 143 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
VTV trades at $221.14, down 0.13% on the day, with a bullish technical signal from moving averages but overbought RSI levels. The ETF offers a 2.3% dividend yield and has attracted institutional inflows, with recent news highlighting its outperformance versus growth funds in 2026. Value stocks are gaining favor amid market rotation away from tech concentration.
Outlook remains positive given value's momentum and institutional interest, though risks include prolonged underperformance versus growth and fee-related long-term tracking differences. The ETF provides stable income and diversification but faces competition from broader market funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
